Theravance BiopharmaTBPH
About: Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Employees: 99
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
0% more funds holding in top 10
Funds holding in top 10: 4 [Q2] → 4 (+0) [Q3]
9% less repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 43
3.69% less ownership
Funds ownership: 97.82% [Q2] → 94.13% (-3.69%) [Q3]
9% less capital invested
Capital invested by funds: $403M [Q2] → $369M (-$34.5M) [Q3]
10% less funds holding
Funds holding: 132 [Q2] → 119 (-13) [Q3]
50% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 26
95% less call options, than puts
Call options by funds: $6K | Put options by funds: $110K
Research analyst outlook
We haven’t received any recent analyst ratings for TBPH.
Financial journalist opinion
